A phase II non-randomised, open-label, single-arm study to assess the efficacy, safety and tolerability of Nexavar (Sorafenib) monotherapy as third line therapy in patients with progressed ovarian epithelial or primary peritoneal cancer.

Trial Profile

A phase II non-randomised, open-label, single-arm study to assess the efficacy, safety and tolerability of Nexavar (Sorafenib) monotherapy as third line therapy in patients with progressed ovarian epithelial or primary peritoneal cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms OCCASIONE
  • Most Recent Events

    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top